MedTrace Logo

Pharmacokinetics and Safety Studies of Esomeprazole Use in Schizophrenia Patients

NCT03333603 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2018-03-29

No results posted yet for this study

Summary

To evaluate the pharmacokinetic and safety for the esomeprazole use for schizophrenia

Conditions

Interventions

DRUG

esomeprazole

esomeprazole 40mg /tab oral Day1-Day14 then 40mg/2 tab oral Day15-Day56

Sponsors & Collaborators

  • National Taiwan University

    collaborator OTHER

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Chih-Min Liu · Visiting Staff

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-23
Primary Completion
2017-01-23
Completion
2017-01-23

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03333603 on ClinicalTrials.gov